Pharmacist Fees

Health written question – answered on 2nd March 2006.

Alert me about debates like this

Photo of John Hemming John Hemming Liberal Democrat, Birmingham, Yardley

To ask the Secretary of State for Health pursuant to the answer of 13 February 2006, Official Report, columns 1759–64W, on pharmacist fees, what the difference is between the generic reimbursement prices and the prices at which (a) Simvastatin, (b) Lisinopril and (c) Amlodipine could be purchased by pharmacists and dispensing doctors; how much would be recovered by a discount inquiry on that basis for each drug; and if she will break down the information in table one by price category for each drug.

Photo of Jane Kennedy Jane Kennedy Minister of State (Quality and Patient Safety), Department of Health

holding answer 28 February 2006

As stated in my reply on 13 February 2006, Hansard, columns 1760–63, simvastatin, lisinopril and amlodipine are included in the new category M in the drug tariff which was introduced in April 2005. The new arrangements for the community pharmacy contractual framework, together with category M are managed to deliver funding for the contractual framework of 1.766 billion in 2005–06. Of this sum, 0.5 billion is derived from margins on medicines retained by community pharmacy contractors and as a result market prices available to contractors will in most cases be less than reimbursement prices paid to contractors. The Department has arrangements in place agreed under the pharmacy contractual framework to ensure that the contract sum is delivered. This is based on information from a sample of pharmacy contractors submitted on a commercial-in-confidence basis.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.

Annotations

No annotations

Sign in or join to post a public annotation.